Colinz Labs (531210)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 12.16 and PEG of 0.20 suggest the market is not paying a premium if the reported 60% profit growth can be sustained.
• Book value of ₹41.85 covers roughly 64% of the ₹65.10 price, providing a modest asset cushion at P/B of 1.56.
• Piotroski F-Score of 6/9 points to moderate financial health rather than acute distress.
• Annual profitability, implied by the P/E, means this is not a shell but a tiny earning business.

Concerns

• ROE of 5.29% and ROCE of 6.72% are far too low to indicate a durable moat or strong capital allocation.
• Latest quarter sales of ₹1 crore and net profit of ₹0 crore make the headline 60% profit growth look fragile and low-base.
• Sales growth is negative at -2.72% and dividend yield is 0.00%, so total return depends only on uncertain price gains.
• Promoter holding and debt/equity are N/A, leaving insufficient transparency for a microcap investment.

AI Analysis

At ₹65.10, Colinz Labs is a ₹16-crore microcap. Graham would remind me that small size is neither a sin nor a virtue; the numbers must speak. Today they speak softly. A P/E of 12.16 and a profit growth of 60% create the illusion of a bargain, and the PEG of 0.20 looks seductive. But I have seen many such illusions. Sales growth is minus 2.72%, and the latest quarter shows just ₹1 crore of sales with zero net profit. That tells me the 60% profit growth is earning off a very low or unstable base, not from a durable franchise. No dividend, so the only return is eventual price appreciation. ROE of 5.29% and ROCE of 6.72% are far below what I expect from a business with pricing power. The book value of ₹41.85 and P/B of 1.56 mean assets cover roughly two-thirds of the market price; that provides a little cushion, but in a small pharma company, book value can erode. The Piotroski score of 6/9 is moderate and hints at some improvement, so I will not call it a bad business, just an unproven one. Is it a turnaround? Possibly. But I need evidence: sales must stop falling, quarterly profits must become visible and repeatable, and returns on capital must head toward 10 to 15 percent. Until then, this belongs in the 'too hard' pile. In this market, patience is the price of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer